This company listing is no longer active
Ananda Pharma (ANA) Stock Overview
Ananda Pharma Plc, along with its subsidiaries, operates as a biopharmaceutical company that develops cannabidiol-based medicine to treat endometriosis and chemotherapy-induced peripheral neuropathy chronic conditions across the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ANA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Ananda Pharma Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.00055 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | 0.65 |
| 1 Month Change | -75.56% |
| 3 Month Change | -80.00% |
| 1 Year Change | -87.36% |
| 3 Year Change | -89.52% |
| 5 Year Change | -73.17% |
| Change since IPO | -93.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANA | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -31.3% | -3.0% | -1.8% |
| 1Y | -87.4% | 4.8% | 15.2% |
Return vs Industry: ANA underperformed the UK Pharmaceuticals industry which returned 26% over the past year.
Return vs Market: ANA underperformed the UK Market which returned 20.7% over the past year.
Price Volatility
| ANA volatility | |
|---|---|
| ANA Average Weekly Movement | 57.0% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: ANA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: ANA's weekly volatility has increased from 29% to 57% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 9 | Melissa Sturgess | anandadevelopments.com |
Ananda Pharma Plc, along with its subsidiaries, operate as a biopharmaceutical company that develops cannabidiol-based medicine to treat endometriosis and chemotherapy-induced peripheral neuropathy chronic conditions across the United Kingdom and internationally. Its lead product, MRX1, is in Phase 2a feasibility trials for endometriosis-related pain and in a Phase 2 efficacy study to investigate chemotherapy-induced peripheral neuropathy. The company also offers MRX2 and MRX2t, which are cannabinoid-based medicines in Phase 3 clinical trials for refractory epilepsies.
Ananda Pharma Plc Fundamentals Summary
| ANA fundamental statistics | |
|---|---|
| Market cap | UK£2.45m |
| Earnings (TTM) | -UK£4.51m |
| Revenue (TTM) | UK£4.43k |
Is ANA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANA income statement (TTM) | |
|---|---|
| Revenue | UK£4.43k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£4.43k |
| Other Expenses | UK£4.52m |
| Earnings | -UK£4.51m |
Last Reported Earnings
Jul 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.001 |
| Gross Margin | 100.00% |
| Net Profit Margin | -101,771.51% |
| Debt/Equity Ratio | 268.7% |
How did ANA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/23 05:08 |
| End of Day Share Price | 2025/12/19 00:00 |
| Earnings | 2025/07/31 |
| Annual Earnings | 2025/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ananda Pharma Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.